Editorial Commentary
Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?
Abstract
rostate cancer is the most common malignant neoplasm in men, other than non-melanoma skin cancer (1). Although a great proportion of patients may be cured with local therapies, a significant fraction will develop recurrent and metastatic disease.